Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]), any fluoroquinolone (FQ), and any second-line injectable drug (SLID). In 2019, the World Health Organization issued new recommendations for treating patients with drug-resistant TB, substantially limiting the role of SLIDs in MDR-TB treatment and thus putting the definition of XDR-TB into question. Objectives: To propose an up-to-date definition for XDR-TB. Methods: We used a large data set to assess treatment outcomes for patients with MDR-TB exposed to any type of longer regimen. We included patients with bacteriologically confirmed MDR-TB and known FQ and SLID resistance results. We performed logistic regression to estimate the adjusted odds ratios (aORs) for an unfavorable treatment outcome (failure, relapse, death, loss to follow-up), and estimates were stratified by the resistance pattern (FQ and/or SLID) and group A drug use (moxifloxacin/levofloxacin, linezolid, and/or bedaquiline). Measurements and Main Results: We included 11,666 patients with MDR-TB; 4,653 (39.9%) had an unfavorable treatment outcome. Resistance to FQs increased the odds of an unfavorable treatment outcome (aOR, 1.91; 95% confidence interval [CI], 1.63–2.23). Administration of bedaquiline and/or linezolid improved treatment outcomes regardless of resistance to FQs and/or SLIDs. Among patients with XDR-TB, compared with persons receiving no group A drug, aORs for an unfavorable outcome were 0.37 (95% CI, 0.20–0.69) with linezolid only, 0.40 (95% CI, 0.21–0.77) with bedaquiline only, and 0.21 (95% CI, 0.12–0.38) with both. Conclusions: Our study supports a new definition of XDR-TB as MDR-TB and additional resistance to FQ plus bedaquiline and/or linezolid and helps assess the adequacy of this definition for surveillance and treatment choice.
To tackle the tuberculosis (TB) epidemic, in 2014 the World Health Organization launched the End TB Strategy, which includes action to prevent latent TB infection (LTBI) reactivation. Available preventive treatments (PT) are based on either isoniazid (INH) alone or rifampicin (RIF)-containing regimens. This study aims to assess and compare PT completion rates, the occurrence of adverse events, and the time of dropout among those receiving INH-alone or RIF-containing regimens at Villa Marelli Institute, Milan, Italy, covering the period from 1992 to 2018. A total of 19,670 subjects, belonging to various risk groups—mainly young (median age of 29 years), foreign-born (73.3%), and males (58.8%)—with presumed LTBI were prescribed PT (79.3% INH-alone and 20.7% RIF-containing regimens). The treatment completion rate was 79.4% on average, with higher rates among those receiving RIF-containing regimens (85.6%) compared to those that were prescribed INH-alone (77.8%) (p < 0.0001). Notably, some of the high-risk groups for progression of LTBI were more likely to complete PT from RIF-containing regimens. These groups included recent TB contact (89.9%, p < 0.0001), healthcare workers (93.5%, p < 0.0001), and homeless people (76.6%, p < 0.0001). Irrespectively of the chosen PT regimen, most of the dropouts occurred between the start of the treatment and the first follow-up visit (14.3%, 15.2% for those on INH-alone vs. 11.1% for those on RIF-containing regimens). Further shortening of the PT regimen is therefore an aim to ensure adherence, even though it might need further efforts to enhance the patient’s attitude towards starting and carrying out PT.
1 March 2020 in International Journal of Infectious Diseases
Described from Namibia, Trichophiala devylderi Aurivillius, 1879 is a species for which, apart from the original description of female “types”, little is known. Building upon recent observations in the field, investigations in various museums that preserve specimens, and a review of the literature, we describe for the first time the habitat, the known distribution, the morphology of both sexes including the presence of two phenotypes, and the genitalia of both male and female. We also provide genetic information from several specimens that reveal little variation in the standard animal DNA barcode. Finally, we designate a lectotype among the three specimens preserved at the Naturhistoriska Riksmuseet, Stockholm, Sweden.
We report on the first observation for Italy of ab. cremonae Verity, 1911 of Colias croceus (Fourcroy, 1785). This is an extremely rare form characterized by a lemon-yellow background color instead of the orange color typical of the nominal form of Colias croceus. This peculiarity is linked to a genetic mutation that suppresses the expression of orange/red (and pink) coloration due to erythropterin pigments, so that their absence prevents the appearance of orange color on the wings and of the pink color normally observed on the antennae, legs, fringes, and the hair vestiture of the head and thorax. The present report is based on a single male specimen recorded on 7 October 2021 near Benna (Biella, Piedmont), where Colias croceus was abundant. The presence of this aberration is relatively frequent in the Azores Islands (particularly Faial) and has also been reported for Madeira and Hasmieh (Lebanon), the site of origin of the first specimen ever collected. This aberration was previously unrecorded in Italy and is yet unknown in most of continental Europe. Another yellow aberration of Colias croceus, known as ab. erateformis, originally recorded in Romania and, later, from other West Palaearctic (mostly Mediterranean) areas, is considered a different one in which the red pigment is still present.